• See Also
  1. Postsynaptic Alpha Adrenergic Antagonist
  • Indications
  1. Hypertension
    1. Not first-line Antihypertensives, and avoid using as monotherapy (higher risk of CVA and CHF)
  2. Benign Prostatic Hypertrophy
    1. Selective Alpha-1a Antagonists (e.g. Tamsulosin) are preferred
  3. Medical Expulsive Therapy for Ureteral Stone
    1. Replaced by the preferred Selective Alpha-1a Antagonists (e.g. Tamsulosin)
  • Dosing
  1. Hypertension
    1. Start: 1 mg orally at bedtime and titrate dose (Maximum 16 mg/day)
  2. Benign Prostatic Hypertrophy (replaced by Selective Alpha-1a Antagonists)
    1. Start: 1 mg orally at bedtime and titrate every 1-2 weeks doubling dose, to a maximum of 8 mg at bedtime
    2. Extended release formulation (e.g. Cardura XL) 4 mg in am daily (may increase to 8 mg daily after 3-4 weeks)
  3. Medical Expulsive Therapy for Ureteral Stone (replaced by Selective Alpha-1a Antagonists)
    1. Extended release formulation (e.g. Cardura XL) 4 mg orally daily (not FDA approved)
  • Safety
  1. Unknown safety in Pregnancy
  2. Unknown safety in Lactation
  • Mechanism
  1. See Alpha Adrenergic Receptor (Alpha-1 Antagonist)
  2. Peripheral Alpha-1 Adrenergic Antagonist
    1. Arterial and Venous Vasodilation
  • Adverse Effects
  1. See Postsynaptic Alpha Adrenergic Antagonist
  • Drug Interactions
  1. Strong CYP3A4 Inhibitors (e.g. Clarithromycin, Itraconazole)
    1. Risk of increased Doxazosin effects (e.g. Orthostatic Hypotension)
  • Resources
  1. Doxazosin (DailyMed)
    1. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0aaa68a7-f73b-46d8-860f-a76d96897489
  • References
  1. (2020) Med Lett Drugs Ther 62(1598): 73-80
  2. Olson (2020) Clinical Pharmacology, Medmaster Miami, p. 62-3
  3. Hamilton (2020) Tarascon Pocket Pharmacopoeia